Cancer risk for<unk>  on a core biopsy The rate at which breast cancer (ductal carcinoma in situ or invasive mammary carcinoma (all breast cancer except DCIS and LCIS)) is found at the time of a surgical (excisional) biopsy, following the diagnosis of<unk>  on a core (needle) biopsy varies considerably from hospital-to-hospital (range 4-54%). In two large studies, the conversion of an<unk>  on core biopsy to breast cancer on surgical excision, known as "up-grading", is approximately 30%. Cancer risk based on follow-up The relative risk of breast cancer based on a median follow-up of 8 years, in a case control study of US registered nurses, is 3.7.
Atypical ductal hyperplasia
Invasive lobular carcinoma
Ductal carcinoma in situ
Intraductal papilloma
Lobular carcinoma in situ
Fibroadenoma
Atypical hyperplasia
Focal nodular hyperplasia